Halister News

(Bloomberg) -- Bio-Rad Labs initiated with an outperform rating and PT $250 at Well Fargo, with analyst Tim Evans seeing significant margin expansion opportunities.

• Other initiations:
  • TECH market perform, PT $110; says co. has favorable exposure to pharma and a consumables-heavy revenue profile that allows high margins
  • DHR market perform, PT $90; the Cepheid acquisition suggests a renewed focus on clinical diagnostics markets, which we don’t view as favorably as the pharma-focused strategies of certain peers
  • PKI market perform, PT $72; sees some interesting opportunities in emerging markets
• Upgrades A, PT $67; and MTD, PT $660
• Downgrades BRKR to underperform, PT $25
• Sees opportunity in tools from the pharma or the clinical end market (23% and 32% of sector revenue, respectively), which are both expected to exceed GDP growth rates over the next few years; says pharma has enduring structural advantages over clinical

To contact the reporter on this story: Tatiana Darie in New York at tdarie1@bloomberg.net To contact the editors responsible for this story: Arie Shapira at ashapira3@bloomberg.net Brad Olesen